Yes it can be used for glioblastoma, but the question is whether it is effective or not. I've only seen one trial testing Xeloda (capecitabine) for recurrent GBM and it was combined with 6-thioguanine, celecoxib, and CCNU (for those that were previously treated with TMZ). The outcomes were not very impressive, though to be fair these patients had already been treated with a median of 2 prior chemotherapy regimens. In a combination trial like this it's impossible to say how much each agent contributed.
I do know that capecitabine is a standard chemotherapy (in combination with lapatinib) for HER2+ breast cancer metastatic to the brain. (lapatinib is a dual HER2, EGFR inhibitor, and HER2 is in the same receptor family as EGFR).
I just found some more xeloda studies. Thisone states that xeloda is as effective as temozolomide. What do you think? http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871063/
"Tumor response and survival were comparable to standard treatment with temozolomide, although a larger trial comparing each arm independently would have to be conducted to confirm these results"
This trial included only 18 patients.
Median time to progression from diagnosis in the study was about 8 months which is comparable to the phase 3 "Stupp" trial with temozolomide + radiation. However, median overall survival in the capecitabine (Xeloda) trial was no better than with radiation alone.
The study goes on to say that the patients could be divided into those with better or worse outcomes on this treatment depending on a 24- or 8-gene expression profile.
Capecitabine (Xeloda) is actually a prodrug that is converted into 5-fluorouracil. In the Toca511 gene therapy trials, 5-FC is also converted into 5-fluorouracil with the help of a gene that the Toca511 virus inserts into the tumor cells.
Yes it can be used for glioblastoma, but the question is whether it is effective or not. I've only seen one trial testing Xeloda (capecitabine) for recurrent GBM and it was combined with 6-thioguanine, celecoxib, and CCNU (for those that were previously treated with TMZ). The outcomes were not very impressive, though to be fair these patients had already been treated with a median of 2 prior chemotherapy regimens. In a combination trial like this it's impossible to say how much each agent contributed.
ReplyDeleteI do know that capecitabine is a standard chemotherapy (in combination with lapatinib) for HER2+ breast cancer metastatic to the brain. (lapatinib is a dual HER2, EGFR inhibitor, and HER2 is in the same receptor family as EGFR).
http://www.ncbi.nlm.nih.gov/pubmed/20652724 (link to the abstract of the recurrent GBM trial)
ReplyDeleteI just found some more xeloda studies. Thisone states that xeloda is as effective as temozolomide. What do you think?
ReplyDeletehttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871063/
In the discussion, the authors say
Delete"Tumor response and survival were comparable to standard
treatment with temozolomide, although a larger trial
comparing each arm independently would have to be conducted
to confirm these results"
This trial included only 18 patients.
Median time to progression from diagnosis in the study was about 8 months which is comparable to the phase 3 "Stupp" trial with temozolomide + radiation. However, median overall survival in the capecitabine (Xeloda) trial was no better than with radiation alone.
The study goes on to say that the patients could be divided into those with better or worse outcomes on this treatment depending on a 24- or 8-gene expression profile.
Capecitabine (Xeloda) is actually a prodrug that is converted into 5-fluorouracil. In the Toca511 gene therapy trials, 5-FC is also converted into 5-fluorouracil with the help of a gene that the Toca511 virus inserts into the tumor cells.